Shares of Ocugen Inc. OCGN shed 5.16% to $0.83 Wednesday, on what proved to be an all-around positive trading session for the ...

Ocugen Inc. closed $1.23 below its 52-week high ($2.11), which the company reached on March 25th.

Maxim Group has recently initiated Ocugen Inc (OCGN) stock to Buy rating, as announced on October 15, 2024, according to Finviz. Earlier, on March 1, 2023, Chardan Capital Markets had raised the stock ...

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients ...

Geode Capital Management LLC grew its stake in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) by 6.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned ...

The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...

Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.9 which represents a slight increase of $0.09 or 11.11% from the prior close of $0.81. The stock opened at $0.87 and touched a low of ...

State Street Corp lifted its position in Ocugen, Inc. (NASDAQ:OCGN – Free Report) by 7.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 15,824,517 shares of the company’s ...

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board, or DSMB, for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study.

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA ...